World Pharma News Digest - 11.11.2009

0 views
Skip to first unread message

Ruslan David

unread,
Nov 11, 2009, 6:49:29 AM11/11/09
to worldph...@googlegroups.com
Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement 
Bristol-Myers Squibb Company (NYSE:BMY) and Alder Biopharmaceuticals, Inc., announced a global agreement for the development and commercialization of ALD518, a novel biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis. 
Read more... 
http://www.worldpharmanews.com/content/view/1016/1/
 
International Diabetes Federation drives global action ahead of World Diabetes Day 
In many countries, November is diabetes awareness month, with November 14 - World Diabetes Day - the most significant date on the diabetes calendar. The need to increase diabetes awareness grows ever year with the increasing impact of the disease worldwide. 
Read more... 
http://www.worldpharmanews.com/content/view/1015/1/
 
WHO Grants Prequalification for Global Use to GSK's 10-Valent Synflorix™ Vaccine 
The World Health Organization (WHO) has awarded prequalification for global use of Synflorix™, GlaxoSmithKline Biologicals' pneumococcal conjugate vaccine. This is the first prequalification for a vaccine against pneumococcal disease, which is a life-threatening disease affecting many children under five in developing countries. 
Read more... 
http://www.worldpharmanews.com/content/view/1014/1/
 
European Partnership for Action against Cancer 
At the end of September month, in Brussels, over 300 cancer organisations, patients and cancer survivors, health professionals, researchers, health authorities and health ministers gather to mark the official launch of the European Partnership for Action against Cancer. 
Read more... 
http://www.worldpharmanews.com/content/view/1013/1/
 
Amgen Announces Overall Survival Results for Vectibix(R) in First-Line Metastatic Colorectal Cancer 
Amgen (Nasdaq: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal cancer (mCRC) failed to meet a secondary endpoint of overall survival. 
Read more... 
http://www.worldpharmanews.com/content/view/1012/1/
 
Novartis to expand its human vaccines presence in China 
Novartis has reached an agreement to acquire an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. as part of a strategic initiative to build a vaccines industry leader in this country and expand the Group's limited presence in this fast-growing market segment. 
Read more... 
http://www.worldpharmanews.com/content/view/1011/1/
 
New Merck Begins Operations 
Merck & Co., Inc. (NYSE: MRK) outlined its global plans following the completion of Merck's merger with Schering-Plough Corporation. The new Merck is a global health care leader aimed at providing innovative, distinctive products and services that save and improve lives, while satisfying customer needs and creating long term shareholder value. 
Read more... 
http://www.worldpharmanews.com/content/view/1010/1/
 
World's largest malaria vaccine trial now underway in seven African countries 
A pivotal efficacy trial of RTS,S, the world's most clinically advanced malaria vaccine candidate, is now underway in seven African countries: Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique and Tanzania. The trial, which is expected to involve up to 16,000 children, is on schedule, with more than 5,000 children already enrolled, researchers announced Tuesday at the 5th Multilateral Initiative on Malaria Pan-African Malaria Conference. 
Read more... 
http://www.worldpharmanews.com/content/view/1009/1/
 
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China 
Novartis announced a USD 1 billion investment over the next five years, increasing R&D activities in China and confirming Novartis' long term commitment to China's further economic development, health reform and improving the health care of the Chinese people. The Novartis investment will include a significant expansion of The Novartis Institute of BioMedical Research (CNIBR) in Shanghai. 
Read more... 
http://www.worldpharmanews.com/content/view/1008/1/
 
Pfizer and Medivation Initiate Two Phase 3 Trials of Dimebon 
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer's disease (AD). 
Read more... 
http://www.worldpharmanews.com/content/view/1007/1/
 
PharmaNews.eu / Latest News
 
 
 
 
Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with Diabetes
http://www.pharmanews.eu/abbott/375-abbotts-xience-prime-and-xience-vr-receive-indications-in-europe-for-treatment-of-patients-with-diabetes
 
 
 
Novartis announces USD 1 billion investment to build largest pharmaceutical R&D institute in China
http://www.pharmanews.eu/novartis/372-novartis-announces-usd-1-billion-investment-to-build-largest-pharmaceutical-rad-institute-in-china
 
 
Heinrich Wieland Prize 2009 awarded for outstanding achievements in the synthesis of key natural products
http://www.pharmanews.eu/boehringer-ingelheim/370-heinrich-wieland-prize-2009-awarded-for-outstanding-achievements-in-the-synthesis-of-key-natural-products
 
 
With best regards,
Ruslan David, MD
Administrator/Editor
 
 
PS:
Subscribe to World Pharma News alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=worldpharmanews&loc=en_US
 
Subscribe to PharmaNews.eu alerts by Email (a free service delivered by Google) -
http://feedburner.google.com/fb/a/mailverify?uri=pharmanewseu&loc=en_US
Reply all
Reply to author
Forward
0 new messages